Over 20 years’ experience in assessing the best available evidence to inform health policy in the medical research, pharmaceutical and biotechnology industries. A diverse background in clinical trial management, competitive intelligence, health technology assessment, critical appraisal, and the development of clinical practice guidelines.
Dr. Jorgensen joined HTAnalysts in March 2013 and has over 20 years of experience in the medical research, pharmaceutical and consulting industries. While with HTAnalysts, Margaret has led the development of 2 clinical practice guidelines, conducted numerous rigorous systematic reviews and contributed to several PBAC and MSAC reimbursement submissions. Dr. Jorgensen has also participated in the preparation of manuscripts and the adaptation of global health economics models for a variety of industry and non-industry clients. During her career, Dr Jorgensen has gained diverse therapeutic knowledge across a range of disease areas including infectious diseases, oncology, mental health, natural therapies and patient blood management.
Prior to joining HTAnalysts, Dr. Jorgensen worked for the Health Policy Division of The George Institute for Global Health where she provided key stakeholders such as the Bill & Melinda Gates Foundation, the World Bank, and the International AIDS Vaccine Initiative with evidence-based research to support policy decisions for neglected diseases. This included the development of a Global Survey for Funding of Innovation for Neglected Diseases and an in-depth analysis of future funding demands for malaria drug and vaccine development. Margaret gained her extensive experience in critical appraisal, data analysis, treatment surveys, decision trees, and report writing whilst employed as a research analyst at Decision Resources, Inc. Here, she provided biopharmaceutical companies with and in-depth research and competitive intelligence as to the trends, emerging developments, and market potential of drugs & vaccines within the major pharmaceutical markets (US, Japan, UK, Germany, France, Italy, and Spain). Dr. Jorgensen also has prior experience managing late-phase clinical trials across several geographic regions. Margaret obtained her Bachelor of Medical Science (Hons) degree from the University of Sydney and completed her Ph.D. at the University of New South Wales. She received postdoctoral training at the Harvard University School of Public Health and has published a number of articles in peer-reviewed journals.